Health experts clash over use of certain drugs to treat COVID-19
Health officials around the world are clashing over the use of certain drugs for COVID-19, leading to different treatment options for patients depending on where they live.
On Friday, a World Health Organization guidelines panel advised against using the antiviral remdesivir for hospitalized patients, saying there’s no evidence it improves survival or avoids the need for breathing machines.
But in the U.S. and many other countries, the drug has been the standard of care since a major, government-led study found other benefits — it shortened recovery time for hospitalized patients by five days on average, from 15 days to 10.
Within the U.S., a federal guidelines panel and some leading medical groups have not endorsed two other therapies the Food and Drug Administration authorized for emergency use — Eli Lilly’s experimental antibody drug and convalescent plasma, which is derived from the blood of COVID-19 survivors. The groups say there isn’t enough evidence to recommend for or against them.
Doctors also remain uncertain about when and when not to use the only drugs known to improve survival for the sickest COVID-19 patients: dexamethasone or similar steroids.
And things got murkier with Thursday’s news that the anti-inflammatory drug tocilizumab may help. Like the key WHO study on remdesivir, the preliminary results on tocilizumab have not yet been published or fully reviewed by independent scientists, leaving doctors unclear about what to do.
“It’s a genuine quandary,” said the University of Pittsburgh’s Dr. Derek Angus, who is involved in a study testing many of these treatments. “We need to see the details.”
Dr. Rochelle Walensky, infectious-disease chief at Massachusetts General Hospital, agreed.
“It’s really hard to practice medicine by press release,” she said on a podcast Thursday with a medical journal editor. Until the National Institutes of Health’s guidelines endorse a treatment, “I’m really reluctant … to call that ‘standard of care.’”
Angus said there are legitimate questions about all of the drug studies.
“It’s not unusual for professional guidelines to disagree with each other, it’s just that it’s all under the microscope with COVID-19,” he said.
The rift over remdesivir, sold as Veklury by Gilead Sciences Inc., is the most serious. The WHO guidelines emphasize that the drug does not save lives, based heavily on a WHO-sponsored study that was larger but much less rigorous than the U.S.-led one that found it had other benefits.
The drug is administered intravenously for around five days, and its high cost and lack of “meaningful effect” on mortality make it a poor choice, the WHO panel concluded.
Gilead charges $3,120 for a typical treatment course for patients with private insurance and $2,340 for people covered by government health programs in the U.S. and other developed countries. In poor or middle-income countries, much cheaper versions are sold by generic makers.
Price may be keeping demand for remdesivir low. In October, U.S. health officials said that hospitals had bought only about one-third of the doses that they were offered over the previous few months, when the drug was in short supply. Between July and September, 500,000 treatment courses were made available to state and local health departments, but only about 161,000 were bought.
In a separate development, the FDA gave emergency authorization Thursday to use of another anti-inflammatory drug, baricitinib, to be used with remdesivir. Adding baricitinib shaved an additional day off the average recovery time for severely ill hospitalized patients in one study.
Lilly sells baricitinib now as Olumiant to treat rheumatoid arthritis, which occurs when a patient’s mistaken or overreacting immune system attacks joints, causing inflammation. An overactive immune system also can lead to serious problems in coronavirus patients.
Get our free Coronavirus Today newsletter
Sign up for the latest news, best stories and what they mean for you, plus answers to your questions.
You may occasionally receive promotional content from the Los Angeles Times.